retatrutide long term Is Right for You? Understanding the Eligibility Criteria Retatrutide — Limitless

GLP-1 therapies have already begun changing lifestyles

Preclinical trials demonstrate that this co-agonist improves glucose tolerance, indicating that the GLP-1 activity can successfully buffer the hyperglycaemic potential of GcgR agonism

doi: 10.1186/s12906-015-0859-1

Glycemic Efficacy Studies have shown that A1c reductions are similar to, or slightly less, than those observed with sulfonylurea or metformin treatment when meglitinides are used as monotherapy (22,42)

Wegovy (semaglutide) dosage starts at 0.25 mg and is increased to a maximum maintenance dose of 7.2 mg

Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL et al (1996)